semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Multiple Sclerosis MS patients diagnosed with clinically definite MS according to the McDonald (Polman et al., 2005) Being on GA monotherapy (20mg/day sc) for at least 24 months prior to the 24-month MRI scan Having baseline clinical MRI scan that included SWI-filtered phase imaging in a 12-month window from the start day of the of the GA (MS patients) Having baseline clinical MRI scan that included SWI-filtered phase imaging (healthy controls) MS patients having a RR disease course (Lublin and Reingold, 1996) Age 18-65 (healthy controls will be matched to MS patients for age and sex) Signed informed consent at the 24-month follow-up Pass MRI health screening MS patients passing contrast screening MS patients having normal kidney function (creatinine clearance >59)  Patients who had a relapse within 30 days prior to MRI baseline scan date Patients who received steroid treatment within 30 days prior to the MRI baseline scan date Women who are pregnant, lactating or of childbearing age who do not consent to approved contraceptive use during the study MS patients who used other imunomodulatory or immunosuppressant treatment other than GA during the follow-up (e.g., IFN-β, mitoxantrone, cyclophosphamide, cladribine, fludarabine, cyclosporine, total body, azathioprine, methotrexate, IVIG, cellcept, natalizumab, etc.) MS patients having abnormal kidney function (creatinine clearance <59)
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Relapsing-remitting Multiple Sclerosis Patients eligible for in this trial have to fulfill all of the following 1. Written informed consent from patients capable of giving or withholding full informed consent must be obtained before any assessment is performed. 2. Male or female subjects aged 18 years. 3. Subjects with relapsing remitting MS defined by 2010 revised McDonald criteria. 4. Patients with Expanded Disability Status Scale (EDSS) score of 0-6.5. 5. Patients under Fingolimod Therapy, according to German label, for at least 6 months at Study Visit 1 (Day 1)  Patients fulfilling any of the following are not eligible for in this study: 1. Patients, who are registered in any patient support program (e.g. Extracare) 2. Patients with any relevant medically unstable condition, as assessed by the primary treating physician at each site. 3. Any severe disability or clinical impairment that can prevent the patient to meet all study requirements at the investigator's discretion 4. History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin 5. Patients who have received an investigational drug (excluding Fingolimod) or therapy within 90 days or 5 half-lives prior to screening, whichever is longer. 6. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive pregnancy test (serum) 7. Women of childbearing potential unwilling to use contraceptive precautions throughout the study (see section 7.13.6 for details). 8. Simultaneous participation in another clinical trial. Patients, who have already been randomized into this trial earlier must not be included a second time. Study personnel or first degree relatives of investigator(s) must not be included in the study
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Relapsing Remitting Multiple Sclerosis Males and females aged ≥18 years Signed fully informed consent provided as per this protocol and willing to comply with the required scheduled assessments of the protocol Diagnosis of relapsing-remitting multiple sclerosis (McDonald (2010)) with dissemination in time and space Currently treated with a stable dose of Rebif®, or Avonex® for a minimum of 3 months duration prior to the screening visit Active MS with history of at least one flare within the past 12 months or two flares in the past 24 months prior to screening An Expanded Disability Status Scale (EDSS) of 6.0 or less at the screening visit White blood cell count ≥ to 3.5x109 Subject agrees to use barrier contraceptive methods (i.e. diaphragm, cervical cap, contraceptive sponge or condom) with spermicidal foam/gel/cream/suppository, or IUD from study enrolment through 6 weeks after last dose of study medication, unless subject is post-menopausal or otherwise incapable of becoming pregnant by reason of surgery or tubal ligation, or has had a vasectomy. Subject agrees to appropriate contraception method though completion of study  Treatment with any other biological therapies including but not limited to Interferon beta-1b, natalizumab, anti-TNF biologic agents, or other agents intended to reduce TNF ≤ 8 weeks prior to screening or within 5 half-lives of agent prior to screening, whichever is longer Previous treatment with rifabutin and/or clofazimine Previous treatment with amiodarone Oral or parenteral antibiotics in the 4 weeks prior to screening. (Topical antibiotics are permitted.) Use of Methylprednisolone sodium succinate, prednisone, or any other corticosteroid during the 30 days prior to screening Relapse within the 30 days prior to screening, or between screening and baseline Initiation or dose modification of 4-aminopyridine within 60 days of screening Use of azathioprine, 6-mercaptopurine (6-MP), methotrexate, cyclosporine or mycophenolate (CellCept) within 8 weeks prior to screening Use of glatiramer acetate, cyclophosphamide, or plasma exchange within 12 weeks prior to screening Use of mitoxantrone within one year prior to screening
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hemispatial Neglect All stroke patients with parietal lobe and thalamic lesions 2. Stroke duration: within 48 hours 3. Patients willing to participate in the study 4. MRI/ CT scan showing parietal lobe and thalamic lesion 5. Patients with upper limb weakness  Stroke duration more than 1 yr 2. Glasgow Coma Scale (GCS) of less than 7 3. Uncooperative patients
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 20.0-50.0,  Relapsing-remitting Multiple Sclerosis (rrMS) for all Participants The subject has a clinically normal or acceptable medical history and physical examination at screening The subject has an acceptable kidney function (eGFR >60 mL/min/1.73m2) for administration of Gadolinium The subject has a trans-locator protein (TSPO) platelet assay conducted with documented results. for all healthy volunteers The subject has no clinical history or signs of neurological impairment The subject has a normal MRI without central white white matter lesions. specific for participants with relapsing and remitting results sclerosis (rrMS) Subject with a previous diagnosis of rrMS, presenting with (a) clinically active disease at time of screening or, or preferentially, (b) clinically active disease at time of screening and having at least one gadolinium--enhanced lesion on MRI The subject at screening has a MRI scan of sufficient quality for Volume of Interest (VOI) definition and co-alignment with Positron Emission Tomography (PET)  General for all participants The subject has a contraindication for Magnetic Resonance Imaging (MRI) The subject has known allergies to Gadolinium contrast agent The subject has received significant ionising radiation exposure from clinical trials or medical examinations in the last 12 months specific for healthy volunteers The subject has family history of multiple sclerosis (MS) The subject is undergoing monitoring of occupational ionising radiation exposure specific for participants with remitting multiple sclerosis (rrMS) The subject has a past history of cerebrovascular disease or vasculitis
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hepatocellular Cancer Histologically confirmed advanced HCC Barcelona Clinic Liver Cancer stage C or stage B if you cannot tolerate or failed TACE No cirrhosis or Child-Pugh A cirrhosis Measurable lesions All acute toxic effects of any prior treatment have resolved to NCI-CTCAE v4.0 grade 1 or less Able to swallow and retain oral medication  Prior systemic regimens for HCC Uncontrolled hypertension CLIP score > 3 ECOG PS > 1 Clinically apparent central nervous system metastases or carcinomatous meningitis Pregnant or breastfeeding Active or clinically significant cardiac disease Evidence or history of bleeding diathesis or coagulopathy Any pulmonary hemorrhage/bleeding event of NCI-CTCAE v4.0 Grade 2 or higher within 4 weeks of enrollment Presence of a non-healing wound, non-healing ulcer, or bone fracture
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Primary Progressive Multiple Sclerosis Enrolled in the Study Horizon 1.5 (Pro00011196) Enrolled in the Multiple Sclerosis Cohort (Pro00023791) Diagnosed with Primary Progressive Multiple Sclerosis At least 18 years of age  Participants not willing to participate or sign informed consent
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Retinoblastoma Newly diagnosed, untreated intraocular retinoblastoma. Participants previously diagnosed with unilateral retinoblastoma treated surgically, with focal therapy or needing chemotherapy who develop asynchronous involvement of the contralateral eye, or patients with unilateral retinoblastoma treated only with enucleation or focal therapy who develop asynchronous involvement of the contralateral eye, will be eligible for study ECOG Performance Score must be ≤ 2 within two weeks prior to registration Participants must have an adequate liver function, as defined by bilirubin ≤ to 3X upper limit of normal (ULN), and SGOT and SGPT ≤ to 3X ULN Participants must have adequate renal function as defined by serum creatinine ≤ to 3X ULN for age Legal guardians must sign an informed consent indicating that they are aware of this study, the possible benefits, and toxic side effects. Legal guardians will be given a signed copy of the consent form  Previously treated participants Presence of metastatic disease or gross (residual) orbital involvement Participants must not have an invasive infection at time of protocol entry Inability or unwillingness of research participant or legal guardian/representative to give written informed consent
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Intimate Partner Violence She is 18 or older She is currently court supervision at Bronx Community Solutions or a drug treatment court or she is currently on probation She reports using any illicit drug or drinking 4 or more alcoholic drinks in a 6-hour period in the past 90 days or she has been in alcohol or drug treatment in the past 6 months OR if she report attending any drug or alcohol treatment in the past 6 months She reports having had an ongoing intimate, dating or sexual relationship with a male or female partner that lasted 3 or more months in the past year She lives within a 90-minute commute of 125th and Broadway  Ability to speak and understand English is not sufficient to participate in assessments or intervention sessions Inability to complete informed consent process due to a psychiatric or cognitive impairment The participant is unwilling or unable to commit to completing all the activities in the study
Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Relapsing-Remitting Multiple Sclerosis Definite diagnosis of RRMS according to the 2010 revised McDonald (Polman et al., 2011) to 64 years old Indication for on-label treatment with fingolimod (Gilenya®) ac-cording to the current approval EDSS score ≤ 6,0 Neurological stable with no evidence of relapse or corticosteroid treatment within 30 days prior to screening Ability to provide written informed consent Highly effective contraception (Pearl Index < 1), reliable abstinence from any heterosexual relationships, or sterilization of the only partner in women of childbearing potential Negative pregnancy test (HCG rapid test in the urine) at screening and baseline in women of childbearing potential  Patients with MS manifestations other than RRMS Patients with known contraindications to Gilenya® according to the current "Fachinformation", in particular Immunodeficiency syndrome Increased risk of opportunistic infections Severe active or chronic active infections (hepatitis, tuberculosis) History or presence of malignancy (other than localized basal or squamous cell carcinoma of the skin). Severe liver dysfunction (Child Pugh C) Hypersensitivity against active or any other compound of study medication d degree Mobitz Type II or higher degree AV block, Sick-sinus syndrome, or Sinuatrial heart block, Significant QT prolongation (QTc>470 msec (female) or >450 msec (males)) History of symptomatic bradycardia or recurrent syncope, known ischaemic heart disease, cerebrovascular disease, history of myocardial infarction, hypokalaemia, congestive heart failure, history of cardiac arrest, uncontrolled hypertension, or severe sleep apnea. Patients with clinically significant liver, kidney or bone marrow dysfunction, defined by the following laboratory values at the time of screening HB <8.5 g / dl